Editorial Open Access

Bioequivalence: Ensuring Therapeutic Consistency in Drug Products

Abstract

Bioequivalence is a critical concept in pharmaceutical research, representing the absence of significant differences in the bioavailability of two drug products containing the same active pharmaceutical ingredient (API). Demonstrating bioequivalence ensures that generic formulations produce the same therapeutic effect as their branded counterparts[1]. Key factors influencing bioequivalence include drug formulation, pharmacokinetics, absorption, and metabolic pathways. Assessment is primarily based on pharmacokinetic parameters such as peak plasma concentration (Cmax), time to peak concentration (Tmax), and area under the plasma concentration-time curve (AUC). Regulatory authorities worldwide mandate bioequivalence studies for approval of generic drugs, thereby ensuring safety, efficacy, and public confidence. This article discusses the principles, methodologies, factors affecting bioequivalence, regulatory considerations, and clinical significance in drug development.

Kiran A. Sharma

To read the full article Download Full Article | Visit Full Article